亚盛医药(AAPG)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AAPG 亚盛医药

休市中 12-12 16:00:00 EST

30.35

+0.36

+1.20%

盘后30.35

+0.000.00%

16:04 EST

最高30.40	最低30.35	成交量639.00
今开30.39	昨收29.99	日振幅0.17%
总市值28.33亿	流通市值21.73亿	总股本9,333万
成交额1.93万	换手率0.00%	流通股本7,158万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"亚盛医药","latestPrice":30.35,"timestamp":1765573200000,"preClose":29.99,"halted":0,"volume":639,"hourTrading":{"tag":"盘后","latestPrice":30.35,"preClose":30.35,"latestTime":"16:04 EST","volume":1,"amount":30.1,"timestamp":1765573440917},"delay":0,"floatShares":71582800,"shares":93330405,"eps":-1.979486,"marketStatus":"休市中","change":0.36,"latestTime":"12-12 16:00:00 EST","open":30.39,"high":30.4,"low":30.35,"amount":19339.950357,"amplitude":0.001667,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.979486,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":29.99,"postHourTrading":{"tag":"盘后","latestPrice":30.35,"preClose":30.35,"latestTime":"16:04 EST","volume":1,"amount":30.1,"timestamp":1765573440917},"volumeRatio":0.18649311284874245},"requestUrl":"/m/hq/s/AAPG/wiki","defaultTab":"wiki","newsList":[{"id":"2590316824","title":"【直击2025 ASH】亚盛医药耐立克®二线治疗CML-CP临床研究数据更新，更前线治疗潜力明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2590316824","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590316824?lang=zh_cn&edition=full","pubTime":"2025-12-09 09:34","pubTimestamp":1765244040,"startTime":"0","endTime":"0","summary":"此次公布是对该研究在2024 ASH年会口头报告结果的持续更新，展现了更长时间的随访疗效与安全性特征。此次更新的研究结果进一步提示耐立克有望为二线CML-CP患者带来一种安全有效的治疗选择，尤其对那些一线使用二代BCR-ABL1酪氨酸激酶抑制剂治疗失败的患者。此次数据的更新，进一步体现了耐立克为更广泛的CML患者群体提供安全有效治疗选择的潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4842159_ZH42159_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["06855","ASH","AAPG","BK4109","BK4588","LU1261432733.SGD","BK4016","LU2463526074.USD","BK1161","CP","BK1574","BK4139","BK4585"],"gpt_icon":0},{"id":"2589519008","title":"港股异动 | 亚盛医药-B(06855)涨超6% 耐立克®POLARIS-1研究获美国FDA和欧洲EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589519008","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589519008?lang=zh_cn&edition=full","pubTime":"2025-12-05 09:33","pubTimestamp":1764898401,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药-B涨超6%，截至发稿，涨5.67%，报64.2港元，成交额1993.31万港元。消息面上，12月5日，亚盛医药-B发布公告，公司原创1类新药奥雷巴替尼联合化疗治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者的全球注册III期临床研究获美国食品药品监督管理局和欧洲药品管理局同意开展。作为耐立克在欧美监管机构获批的第二个全球注册III期研究，POLARIS-1研究在多国家多中心同步入组，将加速耐立克全球特别是欧美市场的上市进程。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","BK4139","EMA","BK1574","BK4081","AAPG","BK1161"],"gpt_icon":0},{"id":"2589985521","title":"亚盛医药-B(06855)耐立克®一线治疗Ph+ ALL的全球注册III期临床研究获美国FDA和欧洲EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589985521","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589985521?lang=zh_cn&edition=full","pubTime":"2025-12-05 08:03","pubTimestamp":1764893004,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，公司原创1类新药奥雷巴替尼联合化疗治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者的全球注册III期临床研究获美国食品药品监督管理局和欧洲药品管理局同意开展。同时，耐立克在Ph+ ALL领域深度布局，针对Ph+ ALL领域的治疗已获《CSCO恶性血液病诊疗指南》连续推荐，并获CDE突破性疗法认定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1571399168.USD","AAPG","BK4585","BK4107","EMA","BK4588","BK4139","III","06855","BK1574","BK4533","LU0985320562.USD","BK1161","ALL","LU2355687059.USD","LU1699723380.USD","BK4134","BK4081"],"gpt_icon":0},{"id":"2586467228","title":"亚盛医药-B(06855)授出130.45万份受限制股份单位及73.66万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2586467228","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586467228?lang=zh_cn&edition=full","pubTime":"2025-11-27 21:18","pubTimestamp":1764249535,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，截至本公告日期，已根据2022年受限制股份单位计划向2022年受限制股份单位计划的146名获选人士授出130.45万份受限制股份单位，相当于130.45万股股份(2022年进一步授出)。截至本公告日期，公司根据首次公开发售后购股权计划条款向34名获授人授出合共73.66万份购股权，可于行使有关购股权时认购合共73.66万股公司普通股，惟须待购股权获授人接纳后方可作实。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","06855","AAPG","BK1574","BK1161"],"gpt_icon":0},{"id":"2586284951","title":"港股亚盛医药-B涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586284951","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586284951?lang=zh_cn&edition=full","pubTime":"2025-11-26 11:03","pubTimestamp":1764126180,"startTime":"0","endTime":"0","summary":"每经AI快讯，亚盛医药-B(06855.HK)涨超3%，截至发稿，涨3.04%，报64.35港元，成交额4604.84万港元。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-11-26/doc-infysxme3338276.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-11-26/doc-infysxme3338276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK4139","06855","AAPG","BK1161"],"gpt_icon":0},{"id":"2586281468","title":"港股异动 | 亚盛医药-B(06855)涨超3% 首次揭示奥雷巴替尼通过调控脂质代谢发挥抗肿瘤作用全新机制","url":"https://stock-news.laohu8.com/highlight/detail?id=2586281468","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586281468?lang=zh_cn&edition=full","pubTime":"2025-11-26 10:47","pubTimestamp":1764125279,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药-B涨超3%，截至发稿，涨3.04%，报64.35港元，成交额4604.84万港元。研究结果表明奥雷巴替尼在琥珀酸脱氢酶缺陷型GIST中具有良好的疗效与安全性，并首次揭示奥雷巴替尼通过调控脂质代谢发挥抗肿瘤作用的全新机制。据悉，这是迄今为止针对该罕见GIST亚型规模最大的前瞻性临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","AAPG","BK1574","06855","BK1161"],"gpt_icon":0},{"id":"2584327965","title":"亚盛医药盘中异动 早盘急速下跌7.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584327965","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584327965?lang=zh_cn&edition=full","pubTime":"2025-11-19 00:00","pubTimestamp":1763481637,"startTime":"0","endTime":"0","summary":"北京时间2025年11月19日00时00分，亚盛医药股票出现异动，股价大幅跳水7.00%。截至发稿，该股报30.42美元/股，成交量594股，换手率0.00%，振幅0.52%。机构评级方面，在所有3家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。亚盛医药股票所在的生物技术行业中，整体跌幅为0.33%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119000037a70249a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119000037a70249a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","06855","AAPG"],"gpt_icon":0},{"id":"2580220496","title":"亚盛医药-B(06855)耐立克®、利生妥®、APG-5918的多项临床进展将在2025年美国血液学会年会(ASH)展示，其中一项获口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2580220496","media":"智通财经","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580220496?lang=zh_cn&edition=full","pubTime":"2025-11-04 08:21","pubTimestamp":1762215703,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，公司3个品种有多项临床和临床前进展入选第67届美国血液学会年会展示及报告，其中一项获口头报告。此外，公司原创1类新药利沙托克拉共 有 2项临床进展获选第67届ASH年会，其中一项获口头报告。这是该品种的临床进展连续第4年入选 ASH年会。第67届ASH年会将于当地时间2025年12月6 日至12月9日间在美国佛罗里达州奥兰多市以线下结合线上的形式举行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","ASH","APG","BK4129","LU2125909759.SGD","LU1923622291.USD","AAPG","BK4139","BK1574","06855","BK4109","LU2125909916.SGD","LU2463526074.USD"],"gpt_icon":0},{"id":"2569099557","title":"美联储10月降息概率高达92%，港股医药高位回落","url":"https://stock-news.laohu8.com/highlight/detail?id=2569099557","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569099557?lang=zh_cn&edition=full","pubTime":"2025-09-24 10:11","pubTimestamp":1758679917,"startTime":"0","endTime":"0","summary":"美联储于9月18日如期宣布降息25bp，为港股市场提供了较为宽松的流动性环境。但当前距离10月29日议息尚有35天，美联储相关官员的发言在短期内引起较大扰动。据CME FedWatch Tool数据，美联储10月降息25bp的概率为91.9%；12月降息25bp的概率为21.7%，降息50bp的概率为77%。从二级市场来看，聚焦港股市场创新药+CXO的恒生医药ETF连续调整，自阶段高点回落近6%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092410141595415b18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"ea3b3b54e2aa42d2aadd6617f904fcb8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092410141595415b18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4559","SPY","SDS","BK4550","BK4139","BK4581","09606","BK4504","OEF","AAPG","ESmain","SH","BK4534","SSO","UPRO","IVV","09688","SPXU",".SPX","OEX","BK4585","MESmain"],"gpt_icon":0},{"id":"2566698828","title":"每日卖空追踪 | 亚盛医药-B 09月10日卖空量成交12.35万股，卖空比例为5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2566698828","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566698828?lang=zh_cn&edition=full","pubTime":"2025-09-10 16:30","pubTimestamp":1757493041,"startTime":"0","endTime":"0","summary":"亚盛医药-B北京时间09月10日，跌1.68%，卖空量成交12.35万股，较上一交易日减少57.81%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091016350697851d0e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091016350697851d0e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2564781953","title":"亚盛医药-B09月01日主力净流入1697.0万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2564781953","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564781953?lang=zh_cn&edition=full","pubTime":"2025-09-01 16:15","pubTimestamp":1756714535,"startTime":"0","endTime":"0","summary":"09月01日, 亚盛医药-B股价涨0.12%，报收83.25元，成交金额2.4亿元，换手率0.78%，振幅2.77%，量比0.59。亚盛医药-B今日主力资金净流入1697.0万元，上一交易日主力净流出815.6万元。该股近5个交易日下跌3.42%，主力资金累计净流出1557.3万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入5220.1万元，其中净流入天数为8日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250901170942a7090fba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250901170942a7090fba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2562291249","title":"港股生物医药股震荡回调，欧康维视生物跌超15%，百奥赛图、中国抗体跌超8.5%，亚盛医药跌超6%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2562291249","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562291249?lang=zh_cn&edition=full","pubTime":"2025-08-25 10:51","pubTimestamp":1756090312,"startTime":"0","endTime":"0","summary":"港股生物医药股震荡回调，欧康维视生物跌超15%，百奥赛图、中国抗体跌超8.5%，亚盛医药跌超6%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/08/25105152660744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["07226","BK4139","BK1574","YANG","399441","03681","AAPG","BK1161","HSTECH","161726","BK4614","HSCEI"],"gpt_icon":0},{"id":"2562291614","title":"中金：维持亚盛医药-B(06855)跑赢行业评级 升目标价至105港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2562291614","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562291614?lang=zh_cn&edition=full","pubTime":"2025-08-25 10:39","pubTimestamp":1756089589,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持亚盛医药-B2025年/2026年归母净利润预测不变，维持跑赢行业评级，考虑到GLORA-4进展，新适应症空间可见度提升，根据DCF模型，上调目标价19.3%至105港币，离当前股价有15.8%的上行空间。公司1H25收入2.34亿元，主要由于去年同期产生授权收入，1H25业绩符合该行预期。该行认为MDS患者人群广泛，一线治疗存在较大未满足需求，公司利生妥这一布局有望加码其差异化优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334247.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","AAPG"],"gpt_icon":0},{"id":"2561147611","title":"每日卖空追踪 | 亚盛医药-B 08月22日卖空量成交17万股，卖空比例为5.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561147611","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561147611?lang=zh_cn&edition=full","pubTime":"2025-08-22 16:30","pubTimestamp":1755851437,"startTime":"0","endTime":"0","summary":"亚盛医药-B北京时间08月22日，涨0.5%，卖空量成交17万股%，较上一交易日减少39.2%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250822174123a4983e1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250822174123a4983e1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2561476199","title":"亚盛医药-B08月22日获主力加仓1782.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2561476199","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561476199?lang=zh_cn&edition=full","pubTime":"2025-08-22 16:15","pubTimestamp":1755850533,"startTime":"0","endTime":"0","summary":"08月22日, 亚盛医药-B股价涨0.50%，报收90.65元，成交金额2.8亿元，换手率0.82%，振幅3.82%，量比0.68。亚盛医药-B今日主力资金净流入1782.2万元，上一交易日主力净流入1179.5万元。该股近5个交易日上涨5.05%，主力资金累计净流出1001.0万元；近20日主力资金累计净流入6971.9万元，其中净流入天数为9日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250822170525a6f52b47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250822170525a6f52b47&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2561761424","title":"亚盛医药耐立克销售收入同比激增93%，医保覆盖成关键驱动力","url":"https://stock-news.laohu8.com/highlight/detail?id=2561761424","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561761424?lang=zh_cn&edition=full","pubTime":"2025-08-22 12:16","pubTimestamp":1755836163,"startTime":"0","endTime":"0","summary":"亚盛医药近日公布2025年上半年业绩，其核心产品耐立克销售收入同比增长93%，达到人民币2.17亿元。业绩显著增长主要得益于该药物被纳入国家医保目录后覆盖范围的持续扩大，市场可及性进一步提升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082212192194f3cd4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082212192194f3cd4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2561436356","title":"亚盛医药-B(06855)中报观：年内股价翻倍上市新高不断刷新，双“十亿美元分子”打开估值天花板","url":"https://stock-news.laohu8.com/highlight/detail?id=2561436356","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561436356?lang=zh_cn&edition=full","pubTime":"2025-08-21 09:02","pubTimestamp":1755738154,"startTime":"0","endTime":"0","summary":"近日，亚盛医药-B盘中股价触及95.35港元，刷新公司上市以来股价新高。至此，公司年初至今股价已翻倍，涨幅高达100.88%。从亚盛医药最新披露的2025年中报数据来看，报告期内，亚盛医药实现收入人民币2.34亿元。7月10日，亚盛医药1类新药利沙托克拉片(利生妥)正式获批上市，成为国内获批的首款国产BCL-2抑制剂。今年7月8日，亚盛医药宣布了两位资深高管的加入。显然，在第二款“十亿美元分子”顺利上市后，亚盛医药已迈向新的历史发展阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1332543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","AAPG","BK1161","06855","BK4139"],"gpt_icon":0},{"id":"2561105435","title":"亚盛医药-B(06855)中期同比盈转亏至5.91亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2561105435","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561105435?lang=zh_cn&edition=full","pubTime":"2025-08-21 08:59","pubTimestamp":1755737999,"startTime":"0","endTime":"0","summary":"金吾财讯 | 亚盛医药-B(06855)公布，截至2025年6月30日止六个月未经审核中期业绩。公司普通权益持有人应占亏损5.91亿元(人民币，下同)，同比盈转亏。每股基本亏损1.73元，去年同期为盈利0.56元。期内，集团收益2.34亿元，同比减少71.63%。其中，耐立克(奥雷巴替尼)在中国的产品销售较截至2024年6月30日止6个月的人民币1.13亿元，增加人民币1.05亿元或93%至2025年上半年的人民币2.17亿元。期内，研发开支5.29亿元，同比增长19%，主要是由于与集团正在进行的全球临床试验相关的外部研发开支增加。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/MzFkZTQ1MjU5YjFkNTI3NmM3M2EwODA1ODY2NzgzMDk4MzEw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MzFkZTQ1MjU5YjFkNTI3NmM3M2EwODA1ODY2NzgzMDk4MzEw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1964482","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MUCmain","06855","CYB","BK1574","BK1161","UCmain","MCNHmain","CNHmain","AAPG"],"gpt_icon":0},{"id":"2561069480","title":"亚盛医药在港交所公告截至2025年6月30日止六个月收益为人民币2.34亿元同比减少71.6%主要是由于截至2024年6","url":"https://stock-news.laohu8.com/highlight/detail?id=2561069480","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561069480?lang=zh_cn&edition=full","pubTime":"2025-08-21 07:31","pubTimestamp":1755732670,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CYB","AAPG","BK4139","MCNHmain","MUCmain","UCmain","HEXmain","CNHmain"],"gpt_icon":0},{"id":"2561248075","title":"亚盛医药-B(06855)发布中期业绩 收益2.34亿元 耐立克® (奥雷巴替尼)在中国的产品销售同比大幅增长93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561248075","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561248075?lang=zh_cn&edition=full","pubTime":"2025-08-21 07:21","pubTimestamp":1755732077,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布截至2025年6月30日止6个月业绩，该集团期内取得收益为人民币2.34亿元。耐立克 在中国的产品销售较截至2024年6月30日止6个月的人民币1.13亿元，增加人民币1.05亿元或93%至2025年上半年的人民币2.17亿元。截至2025年6月30日止6个月研发开支增加人民币8450万元或19.0%至人民币5.29亿元，主要是由于与集团正在进行的全球临床试验相关的外部研发开支增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1332510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亚盛医药-B(06855)发布中期业绩 收益2.34亿元 耐立克® (奥雷巴替尼)在中国的产品销售同比大幅增长93%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","AAPG","BK4139","BK1161","06855"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascentage.com","stockEarnings":[{"period":"1week","weight":-0.0769},{"period":"1month","weight":-0.0789},{"period":"3month","weight":-0.2499},{"period":"6month","weight":-0.0368},{"period":"1year","weight":0.7594},{"period":"ytd","weight":0.7594}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"亚盛医药集团是一家主要从事血液系统恶性肿瘤治疗药物发现、研发及商业化的控股公司。该公司主营业务是从事开发及销售针对肿瘤、乙肝及老化相关的疾病的新型小规模疗法。该公司的主要产品包括Olverembatinib（HQP1351）、Lisaftoclax（APG-2575）、Alrizomadlin（APG-115）、Pelcitoclax（APG-1252）、APG-5918等产品。该公司的产品主要用于治疗主要血液系统恶性肿瘤，包括慢性粒细胞白血病、急性粒细胞白血病、慢性淋巴细胞白血病、急性淋巴细胞白血病、骨髓增生异常综合症及多发性骨髓瘤。该公司主要在国内市场开展业务。","exchange":"NASDAQ","name":"亚盛医药","nameEN":"ASCENTAGE PHARMA GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚盛医药(AAPG)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚盛医药(AAPG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚盛医药,AAPG,亚盛医药股票,亚盛医药股票老虎,亚盛医药股票老虎国际,亚盛医药行情,亚盛医药股票行情,亚盛医药股价,亚盛医药股市,亚盛医药股票价格,亚盛医药股票交易,亚盛医药股票购买,亚盛医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚盛医药(AAPG)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚盛医药(AAPG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}